【首发】安炎达医药宣布完成天使轮融资，持续聚焦于免疫炎症疾病领域创新药研发和产业化

（原标题：【首发】安炎达医药宣布完成天使轮融资，持续聚焦于免疫炎症疾病领域创新药研发和产业化）

动脉网独家获悉，安炎达医药技术（广州）有限公司（以下简称“安炎达医药”），一家专门针对免疫炎症领域的临床阶段的创新药研发公司，今日正式宣布完成由丹麓资本独家领投的数千万元人民币天使轮融资。这充分显示了医药投资界对安炎达医药在新药管线布局、人才团队建设和未来发展计划等方面的认可、支持和信心。本轮融资将主要用于启动安炎达医药核心管线即MAX-001在海内外一期临床试验，以及进一步搭建具有国际化和医药工业界经验的团队，加速公司免疫炎症疾病领域创新药研发和产业化进程。

对于此次顺利完成天使轮融资，安炎达医药创始人兼首席执行官 Micky D. Tortorella 表示：“我们由衷感谢丹麓资本对安炎达医药的肯定和大力支持，这对一家初创生物医药公司来说尤为关键。安炎达医药于成立之初即明确了战略发展方向，即聚焦于免疫炎症疾病领域创新药研发。通过短短一年左右发展布局，目前已确立了极具竞争力和差异化的药物研发管线，并初步完成研发和管理团队搭建。我相信此次融资将显著加速公司研发管线的开发进度，特别是助力首发管线即MAX-001尽早进入临床测试阶段。我们也诚挚欢迎更多投资者与安炎达医药同仁一道合作，加速相关创新药落地转化，为解决区域乃至全球免疫炎症疾病领域重大且未满足的临床需求作出贡献。”

丹麓资本合伙人李洁博士表示：“PD-1/L1抗体药物已成为多种晚期实体瘤一线疗法，然而75%左右患者出现耐药，因此克服该类耐药代表着极其广阔的运用潜力。安炎达医药首发管线即针对晚期实体瘤PD-1/L1抗体耐药机制，成功吸引了丹麓资本团队的浓厚兴趣。创始人Micky在免疫炎症疾病基础研究和新药开发领域深耕超过25年，具备丰富的国际药企研发经验（杜邦、法玛西亚、辉瑞），同时多年担任中国科学院广州生物医药与健康研究药物研发中心首席技术官，领导建立小分子药物发现平台，成果丰硕。目前，通过短短一年左右时间，公司已布局了四条免疫炎症领域FIC/BIC重磅研发管线，体现出安炎达医药团队高效的执行落地能力。丹麓资本将与安炎达医药团队携手，继续支持其发展壮大。”

安炎达医药成立于2022年，是一家位于广州的临床阶段的生物医药技术公司，聚焦于开发针对免疫炎症领域的创新药，以治疗癌症、疼痛、神经系统疾病和骨关节炎等多种疾病。公司拥有一流的药物化学团队以及遍布全球的强大网络和合作。公司科学团队相信，组织微环境决定了机体免疫系统如何对其周围环境做出反应，细胞外基质的微小变化都可能导致免疫/炎症反应过度反应或反应不足，从而导致疾病发生发展。公司的药物即专门针对组织微环境中的关键机制和途径，旨在纠正这种病理状态下的免疫炎症反应。目前，安炎达医药公司产品组合中有 4 种临床候选药物正在开发中，另外，公司临床前药物发现部门也正在针对各种基于关键免疫炎症的靶点合成及鉴定新化合物。

丹麓资本是一家专注于医疗健康行业的创投机构，系统性布局了包括高值耗材、体外诊断试剂、消费医疗、数字医疗等创新性医疗技术以及创新药、生物技术公司、新型医疗服务等多个领域。丹麓资本致力以优秀的业绩来回报投资者，并希望运用资本的力量，加速现代医疗、医药技术的研发和市场化，以提高全民医疗健康水平，成为值得信赖、基业长青的卓越医疗基金管理公司。

Guangzhou, Guangdong, China – October 20th 2023

InflamaX Pharmaceuticals Ltd, a clinical stage drug discovery company that specializes in making new medicines that target immuno-inflammation is announcing that it has completed an angel-round financing of several tens of millions of RMB, exclusively led by Redhill Capital. This fully demonstrates the recognition and support of the pharmaceutical investment community in the company’s new drug pipeline layout, team construction and future development plans. This round of financing will be used to launch Phase I clinical trials of the pioneering pipeline, MAX-001, at home and abroad, and to further recruit talents with both international and pharmaceutical industry experience to accelerate the development and industrialization of innovative drugs in the field of immuno-inflammation.

Regarding the successful completion of angel-round financing, Micky D. Tortorella, founder and CEO of InflamaX Pharmaceuticals, commented: “We sincerely thank Redhill Capital for its recognition and strong support of our company. I consider it particularly critical for a start-up biotech company. Our company has clearly defined its strategic development direction at the beginning of its establishment, which is to focus on the R&D of innovative drugs in the field of immuno-inflammation. After just one year of development, InflamaX has established a highly competitive and differentiated pipeline. And the R&D and management team have been initially formed. I strongly believe this financing will significantly accelerate the development progress of the company’s pipeline, especially to help our pioneering pipeline, MAX-001, enter into clinical stage. We also sincerely welcome more investors to cooperate with our team to accelerate the implementation and transformation of relevant innovative drugs, which would definitely contribute to address the unmet medical needs in the field of immuno-inflammation in the region and even throughout the world.”

Dr. Jie Li, partner of Redhill Capital, commented: “PD-1/L1 antibody drugs have become first-line treatment for many advanced solid tumors, however, 75% of the patients endure drug resistance. Therefore, any drug that can overcome this kind of resistance represents an extremely promising therapy. InflamaX’s pioneering pipeline MAX-001, which is exactly designed to overcome this type of resistance, has caught the eye of Redhill team. Besides, we’re well noticed that the founder and CEO, Micky, has been in the basic research field and drug development community of immune-inflammatory diseases for more than 25 years. Moreover, Micky has served as the CTO of Drug Discovery Pipeline at Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences for many years, leading the establishment of the small molecule drug discovery platform with fruitful results.. In just about a year of development, InflamaX’s laid out four FIC/BIC pipelines in the field of immuno-inflammation, reflecting an efficient execution capability of the team. Redhill Capital will join hands with the team and provide continuous supports.”

About InflamaX:

Founded in 2022, InflamaX is a clinical-stage biotechnology company located in Guangzhou that specializes in making new medicines that target immuno-inflammation as a means for treating various diseases including cancers, pain, neurological diseases and osteoarthritis. InflamaX boasts a first rate medicinal chemistry team and a strong network and collaborations throughout the world. It is our belief that the tissue microenvironment determines how the immune system responds to its surrounding environment. Small changes in the extracellular matrix can cause an over-reaction or under-reaction in the immune/inflammatory response resulting in disease. Our drugs target key mechanisms and pathways in the tissue microenvironment that correct this incorrect immune/inflammatory response.  We currently have 4 clinical candidate drugs in our portfolio and also have a preclinical drug discovery arm that is making new compounds against various immuno-inflammation based targets.

About Redhill:

Redhill Capital is a venture capital focusing on the medical and health industry. The layout includes high-value consumables, in vitro diagnostic reagents, consumer medicine, digital medicine and other innovative medical technologies, as well as innovative drugs, bio-tech companies, new medical services and other fields. Redhill Capital is committed to rewarding its investors with excellent performance, and hopes to use the power of capital to accelerate the research and development and marketization of modern medicines and medical technology, so as to improve the level of medical care and health for the whole world, and become a trustworthy and everlasting excellent medical fund management company.